Bruno Lucidi has been appointed chief executive officer of AgenTus Therapeutics, Inc., a subsidiary of Agenus that has been established as a dedicated cell therapy company, which will focus on the discovery, development, and commercialization of Adoptive Cell Therapy (ACT). Mr. Lucidi will lead a team of scientists, while leveraging the technologies, intellectual property assets, pipeline, and expertise of parent company Agenus.        Mr. Lucidi brings extensive expertise in drug development...